| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 247.84 | 2.8% | 1.4% |
| Total Income | 247.84 | 2.8% | 1.4% |
| Expenditure | 225.99 | 0.1% | 6.7% |
| PBT | 15.76 | 172.2% | 35.0% |
| Net Profit | 10.65 | 136.7% | 44.5% |
| OPM | 8.82% | 2.63pp | 4.50pp |
| NPM | 4.30% | 2.43pp | 3.55pp |
| EPS | 0.30 | 150.0% | 43.4% |
Novanta Announces Third Quarter 2025 Financial Results
04 May 2026 · 4 May, 8:18 am
Summary
Novanta Inc. reported its financial results for the third quarter of 2025, with GAAP revenue increasing by 1.4% to $247.8 million. GAAP net income was $10.7 million, and diluted EPS was $0.30. Adjusted EBITDA reached $58.1 million, and adjusted EPS was $0.87. The company exceeded expectations for revenue, profit, and adjusted EPS growth, driven by improving business fundamentals and growth in the Advanced Surgery business. For the fourth quarter of 2025, Novanta expects GAAP revenue of approximately $253 million to $257 million.
Key Highlights
- 1
Novanta's third quarter 2025 GAAP revenue increased by 1.4% to $247.8 million.
- 2
The company reported a GAAP net income of $10.7 million for the third quarter 2025.
- 3
Third quarter 2025 GAAP diluted earnings per share was $0.30.
- 4
Adjusted EBITDA for the third quarter 2025 reached $58.1 million.
- 5
Adjusted EPS for the third quarter 2025 was $0.87.
- 6
The company achieved a book-to-bill ratio of 1.03x and saw 17% bookings growth year-over-year.
- 7
Novanta expects GAAP revenue of approximately $253 million to $257 million for the fourth quarter of 2025.
Management Comments
Matthijs Glastra
“We exceeded our expectations for revenue, profit and Adjusted EPS growth in the third quarter, based on improving business fundamentals, strength of continued new product revenues and significant growth in our Advanced Surgery business. In addition, we achieved a book-to-bill of 1.03x and saw 17% bookings growth year-over-year,” “As underlying fundamentals begin to recover across various end markets we serve, in the fourth quarter we expect to see a return to year-over-year organic growth (mid to high single digit reported growth), and solid double-digit Adjusted EPS growth,” “For the full year, we are confident in our ability to deliver on our financial objectives as incremental new product revenue remains on track and is expected to exceed $50 million given particular strength in our Medical Solutions segment.” “Looking forward to full year 2026, we now expect to deliver mid-single digit organic revenue growth as a result of continued momentum in our business and end markets, the strength of new design wins, and our new product launches.”
Informational and educational content only. Not investment advice.